NCT02270034 2022-03-10Study to Evaluate Safety and Activity of Crizotinib With Temozolomide and Radiotherapy in Newly Diagnosed GlioblastomaGrupo Español de Investigación en NeurooncologíaPhase 1 Completed38 enrolled